Prednisolone: Uses, Doses, Side Effects, and How It Compares to Prednisone, Dexamethasone, and Fludrocortisone

What Is Prednisolone and What Is It Used For?

Prednisolone is a synthetic glucocorticoid that binds glucocorticoid receptors in virtually every tissue, suppressing the transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) while inducing anti-inflammatory proteins such as annexin-1. The FDA has approved it for conditions spanning allergy, dermatology, rheumatology, pulmonology, ophthalmology, hematology, and gastroenterology. [1]

The drug's reach is broad precisely because inflammation underlies so many diseases. Rheumatoid arthritis, systemic lupus erythematosus, acute severe asthma, inflammatory bowel disease, autoimmune hepatitis, nephrotic syndrome, and temporal arteritis all appear on the FDA label. Off-label uses include Duchenne muscular dystrophy (a landmark 2015 Cochrane review of 14 trials confirmed strength benefit with deflazacort and prednisone/prednisolone [2]) and prevention of postextubation stridor in pediatric patients.

Beyond immunosuppression, prednisolone is one of three oral glucocorticoids used in physiologic-replacement regimens for primary adrenal insufficiency (Addison's disease), although hydrocortisone remains the first-line choice per the 2016 Endocrine Society Clinical Practice Guideline because its shorter half-life better mirrors the cortisol diurnal rhythm. [3] When hydrocortisone tablets are unavailable or impractical, prednisolone 3 to 5 mg once daily in the morning (plus fludrocortisone for mineralocorticoid replacement) is an accepted alternative.

Prednisolone vs. Prednisone: Why the Distinction Matters Clinically

Prednisolone and prednisone are not the same molecule, even though many clinicians and patients use the names interchangeably. Prednisone is a prodrug. The liver's 11-beta-hydroxysteroid dehydrogenase type 1 enzyme converts prednisone to prednisolone before it can exert any biological effect. [4] In a healthy adult with normal hepatic function, that conversion is rapid and nearly complete, so the clinical difference is small.

The difference becomes medically significant in specific populations:

• Hepatic impairment. Patients with active autoimmune hepatitis, cirrhosis, or severe hepatic dysfunction convert prednisone poorly. A 1976 pharmacokinetic study published in Gut showed that prednisolone plasma levels after oral prednisone were 30 to 50% lower in patients with active liver disease compared with controls. [5] Switching those patients to prednisolone directly bypasses that conversion bottleneck.
• Pediatric dosing. Weight-based dosing in children benefits from the predictable bioavailability of an already-active compound. Most UK and Australian pediatric guidelines preferentially list prednisolone rather than prednisone.
• Formulation availability. Prednisolone oral solution (Orapred, 15 mg/5 mL) is often easier to titrate in young children or patients who cannot swallow tablets.

Equipotency is 1:1. A 20 mg prednisone tablet is therapeutically equivalent to a 20 mg prednisolone tablet in a person with intact liver function. [4]

Dosing Across Conditions

Prednisolone dosing follows a spectrum from physiologic replacement (mimicking the adrenal gland's 5 to 10 mg cortisol-equivalent output) to pharmacologic immunosuppression. The table below summarizes standard starting ranges.

| Indication | Typical Starting Dose | Duration Strategy | |---|---|---| | Adrenal insufficiency (replacement) | 3 to 5 mg/day a.m. | Indefinite; stress-dose rules apply | | Mild-moderate asthma exacerbation | 40 to 50 mg/day | 5 to 7 days, no taper needed | | Rheumatoid arthritis (bridge) | 5 to 10 mg/day | Taper to lowest effective dose | | Systemic lupus, acute flare | 0.5 to 1 mg/kg/day (max 60 mg) | Taper over 4 to 8 weeks | | Autoimmune hepatitis induction | 40 to 60 mg/day | Taper over 4 to 6 weeks; add azathioprine | | Nephrotic syndrome (adult) | 1 mg/kg/day (max 80 mg) | 8 weeks, then alternate-day taper | | Temporal arteritis | 40 to 60 mg/day | Very slow taper over 12 to 24 months | | Duchenne muscular dystrophy | 0.75 mg/kg/day (deflazacort 0.9 mg/kg/day preferred) | Long-term; monitor bone density | | Acute severe ulcerative colitis | 40 mg/day IV methylprednisolone equivalent | Switch to oral after response |

Stress dosing. Any patient on prednisolone at doses above 5 mg/day for more than 3 weeks should carry a steroid emergency card. For minor illness (fever, minor dental work), doubling the daily dose for 48 to 72 hours is standard guidance per the Society for Endocrinology. For major surgery or vomiting, parenteral hydrocortisone 100 mg IM/IV is required because oral absorption is unreliable.

Tapering: Why Abrupt Discontinuation Is Hazardous

The hypothalamic-pituitary-adrenal (HPA) axis suppresses in proportion to dose and duration. Prednisolone above 7.5 mg/day suppresses adrenocorticotropin (ACTH) within days; prolonged suppression can require months of recovery after stopping. [6]

A 2002 British Society for Rheumatology guideline recommends reducing prednisolone by no more than 1 to 2.5 mg every 2 to 4 weeks once the dose falls below 10 mg/day. [7] For courses shorter than 3 weeks at doses below 40 mg/day, the HPA axis recovers quickly enough that no formal taper is required in most patients, though individual variation is real.

Signs of adrenal insufficiency during a too-rapid taper include fatigue, nausea, hypotension, hyponatremia, and hypoglycemia. These are distinct from the inflammatory "flare" that can occur when steroids are reduced too fast in autoimmune conditions. Distinguishing the two requires a short Synacthen (cosyntropin) stimulation test: a peak cortisol below 500 nmol/L (18 mcg/dL) at 30 minutes confirms HPA suppression. [3]

Side Effects: The Full Clinical Spectrum

Short courses (fewer than 3 weeks) carry a modest side-effect burden. Longer or higher-dose therapy introduces a predictable list of adverse effects that correlate with cumulative exposure.

Metabolic. Glucocorticoids stimulate hepatic gluconeogenesis and reduce peripheral glucose uptake. In the GISC-UK cohort of 50,000 patients, oral corticosteroid use was associated with a 37% increased risk of type 2 diabetes (adjusted HR 1.37 to 95% CI 1.28, 1.47). [8] Blood glucose monitoring is appropriate in anyone starting prednisolone above 20 mg/day for more than 5 days, particularly if pre-existing insulin resistance exists.

Bone. Prednisolone inhibits osteoblast function and increases osteoclast activity. Fracture risk rises within the first 3 months of use, before measurable bone density loss appears on DXA scan. The American College of Rheumatology 2022 guideline recommends oral calcium (1,000, 1 to 200 mg/day) and vitamin D (600 to 800 IU/day) for all adults starting prednisolone at any dose expected to last 3 months or longer, and oral bisphosphonate therapy for those at moderate-to-high fracture risk. [9]

Adrenal suppression. Already covered above. The key clinical point: never assume a patient on long-term prednisolone has a functioning stress response without testing.

Cardiovascular. Fluid retention (mild), hypertension, and dyslipidemia all occur. Prednisolone's mineralocorticoid activity is low but non-zero (roughly 0.8x hydrocortisone on a milligram basis), so sodium retention can worsen hypertension at higher doses.

Psychiatric. Euphoria, irritability, insomnia, and, less commonly, steroid-induced psychosis can appear within the first week of high-dose therapy. Risk is dose-dependent; doses above 40 mg/day carry a roughly 5% incidence of significant mood disturbance.

Ocular. Posterior subcapsular cataracts and elevated intraocular pressure with chronic use. Annual ophthalmologic review for patients on long-term prednisolone is prudent.

Growth. Prednisolone at pharmacologic doses suppresses linear growth in children. Alternate-day dosing reduces, but does not eliminate, this effect.

How Prednisolone Compares to Other Corticosteroids

Understanding where prednisolone sits in the corticosteroid family requires comparing potency across two separate axes: glucocorticoid (anti-inflammatory) and mineralocorticoid (sodium-retaining).

| Drug | Glucocorticoid Potency (vs. hydrocortisone) | Mineralocorticoid Potency (vs. hydrocortisone) | Half-life (biologic) | Typical Route | |---|---|---|---|---| | Hydrocortisone (Cortef) | 1x | 1x | 8, 12 h | Oral, IV, IM | | Prednisolone | 4x | 0.8x | 12, 36 h | Oral, IV | | Prednisone | 4x (after conversion) | 0.8x | 12, 36 h | Oral | | Methylprednisolone | 5x | 0.5x | 12, 36 h | Oral, IV, IM | | Dexamethasone | 25, 30x | ~0x | 36, 54 h | Oral, IV, IM | | Fludrocortisone (Florinef) | 10x | 125, 150x | 18, 36 h | Oral only |

Hydrocortisone (Cortef). The closest to endogenous cortisol. Three-times-daily dosing (e.g., 10 mg on waking, 5 mg at noon, 5 mg at 4, 5 p.m.) is the Endocrine Society's preferred schedule for adrenal insufficiency because it mimics the physiologic morning cortisol surge. [3] Hydrocortisone does not work well as a once-daily anti-inflammatory drug because its short half-life means inadequate coverage. It is, however, the drug given intravenously during adrenal crisis.

Dexamethasone. Its near-zero mineralocorticoid activity and long biologic half-life make dexamethasone the glucocorticoid of choice for cerebral edema (4 to 8 mg IV every 6 hours), croup (0.6 mg/kg single dose), and the RECOVERY trial's landmark COVID-19 result: dexamethasone 6 mg/day for 10 days reduced 28-day mortality by 17% in hospitalized patients receiving respiratory support (N=6,425, rate ratio 0.83 to 95% CI 0.75, 0.93, P<0.001). [10] Dexamethasone's long half-life makes it poorly suited for physiologic adrenal replacement because it suppresses the HPA axis around the clock.

Fludrocortisone (Florinef). This is the odd one out. Fludrocortisone is prescribed almost exclusively for its mineralocorticoid properties: it binds mineralocorticoid receptors in the kidney's collecting duct, increasing sodium reabsorption and potassium excretion. Standard dosing for primary adrenal insufficiency (Addison's disease) is 0.05 to 0.2 mg once daily. [3] Orthostatic hypotension, low serum sodium, and high plasma renin activity suggest under-replacement; hypertension, edema, and hypokalemia suggest over-replacement. Prednisolone cannot substitute for fludrocortisone in Addison's disease because prednisolone's mineralocorticoid activity is far too low to maintain adequate sodium balance.

The Endocrine Society's 2016 guideline states: "We recommend that all patients with primary adrenal insufficiency receive glucocorticoid and mineralocorticoid replacement therapy." [3] That means prednisolone (or hydrocortisone) plus fludrocortisone, not either agent alone.

Prednisolone in Adrenal Insufficiency: A Closer Look

Primary adrenal insufficiency (Addison's disease) affects approximately 1 in 7,500 people in Western populations. [11] Secondary adrenal insufficiency (caused by pituitary disease or exogenous steroid suppression) is far more common, with prevalence estimated between 150 and 280 per 100,000. [12]

For physiologic replacement, the goal is to mimic cortisol's normal secretion of 5 to 10 mg/day cortisol-equivalent. With prednisolone's 4-fold greater glucocorticoid potency, that translates to approximately 3 to 5 mg prednisolone daily. Most endocrinologists give the entire daily dose in the morning. Because prednisolone's biologic half-life is 12 to 36 hours, a single morning dose produces relatively flat glucocorticoid exposure through the day, which avoids the insomnia and late-afternoon cortisol excess sometimes seen with twice-daily hydrocortisone in poorly-timed schedules.

A 2016 open-label crossover study (N=64) published in the Journal of Clinical Endocrinology and Metabolism compared once-daily modified-release hydrocortisone with conventional twice-daily hydrocortisone in adrenal insufficiency. Prednisolone was not the intervention, but the results confirmed that diurnal cortisol profile matters for quality of life: patients with closer-to-normal morning cortisol peaks reported better fatigue scores. [13] This principle applies equally when prednisolone is used for replacement: administer it in the morning.

Patients with primary adrenal insufficiency on prednisolone still require fludrocortisone for mineralocorticoid replacement. Prednisolone at replacement doses does not provide sufficient aldosterone-like activity to maintain blood pressure and electrolyte balance.

Drug Interactions Clinicians Commonly Miss

Prednisolone is metabolized by CYP3A4. Drugs that inhibit CYP3A4 (ketoconazole, ritonavir, clarithromycin) can raise prednisolone exposure significantly, increasing both therapeutic and toxic effects. CYP3A4 inducers (rifampicin, phenytoin, carbamazepine) accelerate prednisolone metabolism, reducing plasma levels by up to 50% and potentially precipitating adrenal crisis in dependent patients. [14]

Non-steroidal anti-inflammatory drugs (NSAIDs) combined with prednisolone increase gastrointestinal bleeding risk multiplicatively. A proton pump inhibitor is appropriate whenever prednisolone is prescribed alongside an NSAID.

Live vaccines are contraindicated in patients on immunosuppressive doses of prednisolone (generally defined as above 20 mg/day for more than 14 days or any dose causing measurable immune suppression). Inactivated vaccines may be given but the antibody response may be attenuated.

Monitoring Parameters for Long-Term Use

Patients on prednisolone for more than 3 months need structured monitoring. The following schedule is drawn from British Society for Rheumatology and Endocrine Society guidance:

• Blood pressure and weight: every clinic visit.
• Fasting glucose or HbA1c: at baseline, then every 3 to 6 months.
• Lipid panel: at baseline and annually.
• DXA bone density scan: at baseline if expected treatment is 3 months or longer; repeat after 12 months. [9]
• Ophthalmology review: annually for patients on more than 7.5 mg/day prednisolone long-term.
• Morning cortisol or short Synacthen test: before any planned taper that will bring the dose below physiologic range (below approximately 7.5 mg/day prednisone-equivalent).
• Electrolytes: if any mineralocorticoid effect is suspected (at high prednisolone doses or in volume-sensitive patients).

Special Populations

Pregnancy. Prednisolone crosses the placenta less readily than dexamethasone or betamethasone because 11-beta-hydroxysteroid dehydrogenase type 2 in the placenta converts approximately 90% of prednisolone to inactive prednisone before it reaches the fetus. [15] This makes prednisolone the preferred systemic corticosteroid for maternal indications (lupus flares, asthma, inflammatory bowel disease) where fetal exposure should be minimized. Dexamethasone or betamethasone, by contrast, reach the fetal circulation largely intact and are used intentionally to accelerate fetal lung maturity.

Renal impairment. No dose adjustment is required for renal impairment per FDA prescribing information, but sodium and fluid retention may worsen in patients with chronic kidney disease, and hypertension management requires closer attention.

Elderly patients. Bone and metabolic risks are amplified. The ACR recommends bisphosphonate therapy for postmenopausal women and men over 50 starting prednisolone at any dose expected to last 3 months or longer, regardless of baseline DXA T-score. [9]

Practical Prescribing Tips From the HealthRX Endocrine Team

A few patterns come up repeatedly in telehealth consultations that are worth naming directly.

First, many patients started on "a short course" of prednisolone for back pain or an acute allergic reaction continue the drug far longer than the original prescriber intended because no taper plan was documented. Always specify the taper schedule at the time of prescribing.

Second, patients with autoimmune hepatitis are sometimes given prednisone when prednisolone is the more appropriate choice. The AASLD and European Association for the Study of the Liver (EASL) guidelines both specify prednisolone for induction therapy in autoimmune hepatitis, precisely because the liver is the organ being treated.

Third, fludrocortisone dosing in Addison's disease often goes unreviewed for years. The standard monitoring parameter is plasma renin activity, targeted to the upper half of the normal range. If a patient has been on the same fludrocortisone dose since diagnosis without a renin check, that is a gap worth addressing.